会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明申请
    • ASSOCIATION OF BIOMARKERS WITH PATIENT OUTCOME
    • 生物标志物与患者结果的协调
    • US20120270233A1
    • 2012-10-25
    • US12866836
    • 2009-02-10
    • Donald E. WaldronAlpana WaldronRobert PinardMark Gustavson
    • Donald E. WaldronAlpana WaldronRobert PinardMark Gustavson
    • G01N21/64C12Q1/02C12Q1/48G01N21/17
    • G01N33/57407A61K45/06A61N5/00G01N2800/56
    • The present method relates to quantification of prognostic and predictive biomarkers of the PDK/AKT/mTOR pathway, such as GSK3β, S6, CREB, PTEN, AKT and mTOR, using AQUA® analysis to estimate both patient risk and benefit of treatment to patients diagnosed with glioblastoma. Unlike traditional IHC, the AQUA® system is objective and produces quantitative in situ protein expression data on a continuous scale. Taking advantage of the power of the AQUA system, the present method provides a highly robust and standardized diagnostic assays that can be used in the clinical setting to provide physicians with reliable prognostic and predictive information. Glioblastoma multiform (GBM) remains one of the most aggressive human cancers, and biomarkers that provide prognostic and predictive information would be extremely valuable to both the physician and the patient. A patient's risk may be determined using the prognostic biomarkers of the present method. Such a prognostic determination will allow physicians to identify patients with a relatively ‘good’ or a relatively ‘poor’ prognosis. The benefit of treating specific patients with a specific therapy, may be determined usin̂ the predictive markers of the present method. Treatment with the AGC-family kinase inhibitor enzastaurin, for example, identifies patients that will likely benefit from treatment or not.
    • 本方法涉及使用AQUA®分析来估计PDK / AKT / mTOR途径的预后和预测生物标志物如GSK3和bgr,S6,CREB,PTEN,AKT和mTOR,以评估患者的风险和治疗对患者的益处 诊断为胶质母细胞瘤。 与传统IHC不同,AQUA®系统是客观的,可以连续量产定量的原位蛋白表达数据。 利用AQUA系统的优势,本方法提供了一种高度鲁棒和标准化的诊断测定,可用于临床环境,为医师提供可靠的预后和预测信息。 多形性成胶质细胞瘤(GBM)仍然是最具侵袭性的人类癌症之一,提供预后和预测信息的生物标志物对于医师和患者都是非常有价值的。 可以使用本方法的预后生物标志物确定患者的风险。 这样的预后测定将允许医师鉴定具有相对较好或较差预后的患者。 用特定疗法治疗特定患者的益处可以通过本方法的预测标记来确定。 例如,用AGC-家族激酶抑制剂恩斯特劳林治疗可以确定可能从治疗中获益的患者。